Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

July 1, 2025

Study Completion Date

November 1, 2025

Conditions
Cervical Cancer
Interventions
DRUG

Gemcitabine

"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."

Trial Locations (1)

14080

RECRUITING

National Institute of Cancer, Mexico City

All Listed Sponsors
collaborator

Instituto Nacional de Cardiologia Ignacio Chavez

OTHER

collaborator

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER

lead

National Institute of Cancerología

OTHER_GOV